Corcept Therapeutics Incorporated
CORT
$71.58
$1.121.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 157.21M | 181.89M | 182.55M | 163.80M | 146.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.21M | 181.89M | 182.55M | 163.80M | 146.81M |
| Cost of Revenue | 2.40M | 2.96M | 2.87M | 2.02M | 2.04M |
| Gross Profit | 154.81M | 178.93M | 179.68M | 161.77M | 144.77M |
| SG&A Expenses | 90.66M | 83.37M | 73.75M | 66.94M | 56.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.80M | 156.63M | 135.95M | 127.70M | 116.81M |
| Operating Income | 3.42M | 25.26M | 46.60M | 36.09M | 30.00M |
| Income Before Tax | 9.62M | 31.96M | 52.94M | 41.60M | 34.99M |
| Income Tax Expenses | -10.93M | 1.21M | 5.73M | 6.11M | 7.23M |
| Earnings from Continuing Operations | 20.55M | 30.75M | 47.21M | 35.49M | 27.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.55M | 30.75M | 47.21M | 35.49M | 27.76M |
| EBIT | 3.42M | 25.26M | 46.60M | 36.09M | 30.00M |
| EBITDA | 3.70M | 25.54M | 46.92M | 36.17M | 30.12M |
| EPS Basic | 0.19 | 0.29 | 0.45 | 0.34 | 0.27 |
| Normalized Basic EPS | 0.06 | 0.19 | 0.32 | 0.26 | 0.22 |
| EPS Diluted | 0.17 | 0.26 | 0.41 | 0.32 | 0.25 |
| Normalized Diluted EPS | 0.05 | 0.17 | 0.29 | 0.24 | 0.20 |
| Average Basic Shares Outstanding | 104.11M | 103.64M | 103.37M | 103.12M | 102.79M |
| Average Diluted Shares Outstanding | 119.82M | 118.46M | 113.72M | 111.24M | 109.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |